Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1177/10600280211064306

http://scihub22266oqcxt.onion/10.1177/10600280211064306
suck pdf from google scholar
35021920!ä!35021920
PDF vom PMID35021920  :  Publisher

suck abstract from ncbi

pmid35021920
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Evaluation of the Clinical Impact of Thromboprophylaxis in Patients With COVID-19 Following Hospital Discharge #MMPMID35021920
  • Courtney LA; Trujillo TC; Saseen JJ; Wright G; Palkimas S
  • Ann Pharmacother 2022[Sep]; 56 (9): 981-987 PMID35021920show ga
  • BACKGROUND: Data are limited regarding the incidence of thromboembolism post-hospital discharge among COVID-19 patients. Guidelines addressing the role of extended thromboprophylaxis for COVID-19 patients are limited and conflicting. OBJECTIVE: The purpose of this study was to evaluate the incidence of post-discharge thromboembolic and bleeding events and the role of thromboprophylaxis among COVID-19 patients. METHODS: A retrospective analysis was conducted of hospitalized patients with symptomatic COVID-19 infection who were discharged from a University of Colorado Health (UCHealth) hospital between March 1, 2020, and October 31, 2020. The primary outcome was objectively confirmed thromboembolism within 35 days post-discharge. The main secondary outcome was the incidence of bleeding events within 35 days post-discharge. Outcomes were compared between those who received extended prophylaxis and those who did not. RESULTS: A total of 1171 patients met the study criteria. A total of 13 (1.1%) of patients had a documented thromboembolic event and 10 (0.9%) patients had a documented bleeding event within 35 days post-discharge. None of the 132 patients who received extended prophylaxis had a thromboembolic event compared to 13 of 1039 who did not receive extended prophylaxis (0 and 1.3%, respectively; P = .383). The incidence of bleeding was higher among patients who received extended prophylaxis compared to those who did not (3.0% vs 0.6%, P = .019). CONCLUSIONS AND RELEVANCE: These results suggest that post-discharge extended prophylaxis may be beneficial for select COVID-19 patients, while carefully weighing the risk of bleeding. Application of our findings may assist institutions in development of thromboprophylaxis protocols for discharged COVID-19 patients.
  • |*COVID-19/complications[MESH]
  • |*Venous Thromboembolism/prevention & control[MESH]
  • |Aftercare[MESH]
  • |Anticoagulants/adverse effects[MESH]
  • |Hemorrhage/chemically induced[MESH]
  • |Hospitals[MESH]
  • |Humans[MESH]
  • |Patient Discharge[MESH]
  • |Retrospective Studies[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    981 9.56 2022